A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma

Conditions: Hepatocellular Carcinoma Interventions: Biological: AK104+AK112 Sponsors: Harbin Medical University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials